[
  {
    "ts": "2025-11-13T03:16:24+00:00",
    "headline": "Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships",
    "summary": "Curious whether Gilead Sciences is a hidden gem or if the current stock price already reflects all its upside? Let’s break down the numbers and see if there's value yet to be uncovered. After a strong year with a 37.2% gain and an impressive 34.3% jump year to date, the market’s perception of Gilead’s risk and growth potential appears to be evolving. Recent headlines highlight the company’s steady stream of new treatment approvals and strategic partnerships, both of which have bolstered...",
    "url": "https://finance.yahoo.com/news/assessing-gilead-34-rally-recent-031624801.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0860caaa-8e8c-3b68-b0f9-78d2f7c525e9",
      "content": {
        "id": "0860caaa-8e8c-3b68-b0f9-78d2f7c525e9",
        "contentType": "STORY",
        "title": "Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships",
        "description": "",
        "summary": "Curious whether Gilead Sciences is a hidden gem or if the current stock price already reflects all its upside? Let’s break down the numbers and see if there's value yet to be uncovered. After a strong year with a 37.2% gain and an impressive 34.3% jump year to date, the market’s perception of Gilead’s risk and growth potential appears to be evolving. Recent headlines highlight the company’s steady stream of new treatment approvals and strategic partnerships, both of which have bolstered...",
        "pubDate": "2025-11-13T03:16:24Z",
        "displayTime": "2025-11-13T03:16:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-gilead-34-rally-recent-031624801.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-gilead-34-rally-recent-031624801.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T13:30:00+00:00",
    "headline": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial",
    "summary": "FOSTER CITY, Calif., November 13, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file t",
    "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000346.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "59c9c832-122c-3470-a561-ee21d0388e25",
      "content": {
        "id": "59c9c832-122c-3470-a561-ee21d0388e25",
        "contentType": "STORY",
        "title": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial",
        "description": "",
        "summary": "FOSTER CITY, Calif., November 13, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file t",
        "pubDate": "2025-11-13T13:30:00Z",
        "displayTime": "2025-11-13T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7b7a8bbdda2a36d520cf28df62b90a14",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kO4iq3qV3dqS6SvUlhWAlQ--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7b7a8bbdda2a36d520cf28df62b90a14.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W5vLtvRkVJMesMjXTT2K7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7b7a8bbdda2a36d520cf28df62b90a14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-investigational-single-tablet-regimen-133000346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T14:10:11+00:00",
    "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More",
    "summary": "Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More",
    "url": "https://247wallst.com/investing/2025/11/13/here-are-thursdays-top-wall-street-analyst-research-calls-abbvie-applovin-autozone-booking-holdings-coreweave-doordash-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b8cea827-566d-37fc-87c2-10283d2de53d",
      "content": {
        "id": "b8cea827-566d-37fc-87c2-10283d2de53d",
        "contentType": "STORY",
        "title": "Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More",
        "pubDate": "2025-11-13T14:10:11Z",
        "displayTime": "2025-11-13T14:10:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b",
          "originalWidth": 1366,
          "originalHeight": 767,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rYIxCrA6AKDxNsz2Qsl7cA--~B/aD03Njc7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b.cf.webp",
              "width": 1366,
              "height": 767,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iZWmPqjiX4v_sd4A3P5Kcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/13/here-are-thursdays-top-wall-street-analyst-research-calls-abbvie-applovin-autozone-booking-holdings-coreweave-doordash-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/thursday-top-wall-street-analyst-141011927.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FAST"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "CRS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BKNG"
            },
            {
              "symbol": "NKE"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "PCH"
            },
            {
              "symbol": "COO"
            },
            {
              "symbol": "TT"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "AZO"
            },
            {
              "symbol": "DLTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]